What is it about?
Clinical trials suggested human serum albumin binding was too high affinity to flavopiridol, casuing poor clinical results. This paper, using a diagnostic signal at 284nm observed by circular dichroism upon binding shows flavopridiol binding is not too high affinity.No protein secondary structure changes are found.
Featured Image
Why is it important?
Flavopiridol is a potent cyclin-dependant kinase inhibitor, and suggest drug for chronic lymphatic leukemia. Clinical trials have struggled to optimise dosing schedules. This work shows flavopiridol human serum albumin binding is not the cause of its poor clinical performance.
Perspectives
This work sparked an interest in drug discovery and how it links to clinical trials.
Daniel Myatt
Read the Original
This page is a summary of: The binding of flavopiridol to blood serum albumin, Chirality, January 2010, Wiley,
DOI: 10.1002/chir.20925.
You can read the full text:
Contributors
The following have contributed to this page
